Clinical trials: Enoxaparin
Sars-CoV2, COVID
Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients
The aim of this study is to test the hypothesis that prophylaxis of severe COVID-19 patients with treatment dose LMWH leads to better thromboembolic-free outcomes and associated complications during hospitalization than…
- Trial name
- NCT04401293
- Testing
- Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
- Where
- 6 sites in United States
- Volunteers
- 257 people
- Sponsor
- Northwell Health
Thromboembolic Complications
Thrombelastography Based Dosing of Enoxaparin
The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many times enoxaparin (or Lovenox®) is given to patients who are at a higher risk of developing clots in their legs or lungs.
- Trial name
- NCT00990236
- Testing
- Enoxaparin dose adjusted Lovenox based on TEG, Enoxaparin 30 mg BID
- Where
- 3 sites in United States
- Volunteers
- 185 people
- Sponsor
- Oregon Health and Science University
Percutaneous Coronary Intervention
Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)
The purpose of this study is to evaluate the efficacy and safety of intravenous enoxaparin versus intravenous unfractionated heparin (UFH) in patients undergoing non-emergent PCI, as assessed by measuring the incidence of…
- Trial name
- NCT00077844
- Testing
- Enoxaparin sodium
- Volunteers
- 3,532 people
- Sponsor
- Sanofi
Thrombosis
Efficacy and Safety of Short-term Postoperative Anticoagulant Therapy to Prevente Thrombosis in Arterovenous Fistula
Many guidelines at home and abroad advocate that arteriovenous fistula should be the first choice of permanent vascular access, but it is easy to form thrombus in a short time after arteriovenous fistula molding, resulting in…
- Trial name
- EASOAT (NCT04164693)
- Testing
- Low molecular weight heparin, non anticoagulant therapy group
- Where
- China
- Volunteers
- 287 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Obesity, Venous Thrombosis
Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT
Deep vein thrombosis(DVT) is a common complication in hospitalized medical patients. Consensus guidelines recommend using medications such as heparin or low-molecular-weight heparins (LMWH) to prevent DVT in these patients.
- Conditions
- Obesity, Venous Thrombosis, Anticoagulants
- Trial name
- NCT00585182
- Testing
- Enoxaparin 0.5 mg/kg once daily
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Utah
Spinal Cord Injuries, Venous Thromboembolism
Apixaban For Thromboprophylaxis In Patients With Acute Spinal Cord Injury
Thromboprophylaxis options are limited for patients with acute spinal cord injury (SCI) and there are no studies on direct oral anticoagulants (DOACs) for thromboprophylaxis in this population.
- Trial name
- NCT03200613
- Testing
- Apixaban, Low molecular weight heparin
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- McMaster University
Cancer, Rivaroxaban
Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin
The Valeria trial will provide high-quality evidence regarding the efficacy and safety of oral rivaroxaban in thromboprophylaxis after gynecological pelvic cancer surgery in comparison with standard parenteral enoxaparin.
- Conditions
- Cancer, Rivaroxaban, Venous Thromboembolism, Thromboprophylaxis
- Trial name
- VALERIA (NCT04999176)
- Testing
- Rivaroxaban, Enoxaparin
- Where
- Brazil
- Volunteers
- 440 people
- Sponsor
- André Luiz Malavasi Longo de Oliveira
Venous Thromboembolism
Low Molecular Weight hEparin vs. Aspirin Post-partum
This is single centre pilot, randomized controlled trial assessing postpartum prophylactic anticoagulation with 3 weeks of LMWH followed by 3 weeks of Aspirin compared to standard of care of prophylactic LMWH for 6 weeks at…
- Trial name
- LEAP (NCT05058924)
- Testing
- Prophylactic low molecular weight heparin, Low molecular weight heparin and low-dose aspirin
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Mount Sinai Hospital, Canada
Venous Thromboembolism
Dose-confirmatory Bridging Study in Total Hip Replacement
The objective of this dose-confirmatory bridging study is to investigate the safety and efficacy of rivaroxaban 5 to 10 mg once-daily (od) dosing in the prevention of venous thromboembolism (VTE) in Japanese patients undergoing…
- Trial name
- NCT01205932
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 41 sites in Japan
- Volunteers
- 402 people
- Sponsor
- Bayer
This Study Will Provide Data Comparing Safety of LMWH Versus UFH in the Treatment of Acute PE Cases Who Require Thrombolytic Treatment.
Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism
Purpose and rationale: Acute pulmonary embolism (PE) is a common and often fatal disease, with an approximately 30% mortality rate without treatment. Treatment is important to reduce mortality and recurrence in acute PE.
- Trial name
- NCT01956955
- Testing
- enoxaparin ,alteplase, unfractionated heparin
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Ataturk University
Coronavirus Infection
Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial
Pragmatic randomized clinical trial of patients admitted to the hospital with confirmed COVID-19 infection and elevated D-Dimer.
- Trial name
- ACTION (NCT04394377)
- Testing
- Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed, Group 2: control group with enoxaparin 40mg/d
- Where
- 36 sites in Brazil
- Volunteers
- 615 people
- Sponsor
- Brazilian Clinical Research Institute
Acute Cholecystitits
The Role of Antibiotic Treatment in Patients With Acute Mild Cholecystitis - A Prospective Randomized Controlled Trial
The treatment of acute cholecystitis includes limited oral intake, antibiotics and early or delayed surgery. To date there are no randomized trials proving the benefit of antibiotic treatment.
- Trial name
- NCT00557453
- Testing
- Antibiotic treatment, No antibiotics
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Hadassah Medical Organization
Physiologic Venous Dilation, Air Travel
Randomized Assessor-Masked Trial of Moderate Graduated Compression Stockings for Popliteal Vein Dilation During Long-Haul Economy-Class Air Travel After Aesthetic Surgery
This randomized assessor-masked trial will evaluate whether knee-high moderate graduated compression stockings reduce popliteal vein dilation during long-haul economy-class air travel to Bogota.
- Trial name
- NCT07810192
- Testing
- Enoxaparine, Knee-High Graduated Compression Stockings, Standardized Bilateral Popliteal Vein Ultrasound
- Where
- Colombia
- Volunteers
- 160 people
- Sponsor
- Research Inc
Venous Thromboembolism
Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and prevent blood clot which may form after total hip replacement operation.
- Trial name
- NCT00329628
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 215 sites in United States, Argentina and 26 more
- Volunteers
- 4,541 people
- Sponsor
- Bayer
Pulmonary Embolism, Venous Thromboembolism
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism
This study aims to compare the effectiveness and safety of three treatment strategies (Anticoagulation, Thrombolysis, and Mechanical Thrombectomy) for patients with intermediate-high risk acute pulmonary embolism (PE) in a…
- Trial name
- STRATEGY-PE (NCT07603700)
- Testing
- Anticoagulants, Thrombolytic Agents, Mechanical Thrombectomy Devices
- Where
- China
- Volunteers
- 1,300 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Prevention, Venous Thromboembolism
A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total hip arthroplasty.
- Trial name
- NCT01181167
- Testing
- edoxaban, enoxaparin sodium
- Where
- 2 sites in Japan
- Volunteers
- 610 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Acute Exacerbation Copd, Venous Thromboembolism
Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD
AECOPD increases the risk of VTE.VTE prevention is a long way to go for high-risk VTE patients in China.The incidence of AECOPD complicated with VTE in Asian population is high and the mortality rate is high.Rivaroxaban, a new…
- Trial name
- SUPREME (NCT03277001)
- Testing
- Rivaroxaban, Enoxaparin
- Where
- China
- Volunteers
- 438 people
- Sponsor
- Huashan Hospital
HCC
Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma.
Hepatocellular carcinoma (HCC) is a major health problem worldwide, and most cases are inoperable because of late presentation and underlying cirrhosis.
- Trial name
- NCT02715492
- Testing
- LMWH, TACE
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Sherief Abd-Elsalam
Venous Thromboembolism
The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study
Venous thromboembolism (VTE) is a frequent condition, affecting 1.8 per 1,000 people every year. Admission to hospital is one of the main risk factors for VTE, and could account for up to 20% of all VTE, making VTE prevention in…
- Trial name
- SYMPTOMS (NCT02379806)
- Testing
- Enoxaparin
- Where
- 46 sites in France, Switzerland
- Volunteers
- 2,560 people
- Sponsor
- University Hospital, Brest
Covid19, SARS-CoV Infection
Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection
SARS-CoV-2 infection seems to induce in most critical cases an excessive and aberrant hyper-inflammatory host immune response that is associated with a so-called "cytokine storm", moreover pro-thrombotic derangements of…
- Conditions
- Covid19, SARS-CoV Infection, Pneumonia, Viral, Coagulopathy
- Trial name
- STAUNCH-19 (NCT04528888)
- Testing
- Enoxaparin, Methylprednisolone, unfractionated heparin
- Where
- Italy
- Volunteers
- 210 people
- Sponsor
- Massimo Girardis